BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20633783)

  • 21. Development of bullous pemphigoid during treatment of psoriasis with adalimumab.
    Stausbøl-Grøn B; Deleuran M; Sommer Hansen E; Kragballe K
    Clin Exp Dermatol; 2009 Oct; 34(7):e285-6. PubMed ID: 19438555
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum sickness due to infliximab in a patient with psoriasis.
    Krishnan RS; Hsu S
    J Drugs Dermatol; 2004; 3(3):305-8. PubMed ID: 15176166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced lupus and autoimmune hepatitis secondary to infliximab for psoriasis.
    Dang LJ; Lubel JS; Gunatheesan S; Hosking P; Su J
    Australas J Dermatol; 2014 Feb; 55(1):75-9. PubMed ID: 23651182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab-induced lichen planopilaris.
    Fernández-Torres R; Paradela S; Valbuena L; Fonseca E
    Ann Pharmacother; 2010 Sep; 44(9):1501-3. PubMed ID: 20702759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential complications associated with the use of biologic agents for psoriasis.
    Zeichner JA; Lebwohl M
    Dermatol Clin; 2007 Apr; 25(2):207-13, vii. PubMed ID: 17430757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case of mycosis fungoides with large cell transformation associated with infliximab treatment.
    Suga H; Sugaya M; Toyama T; Sumida H; Fujita H; Kogure A; Igarashi A; Sato S
    Acta Derm Venereol; 2014 Mar; 94(2):233-4. PubMed ID: 23975254
    [No Abstract]   [Full Text] [Related]  

  • 27. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tremfya™ (Guselkumab).
    Abramovits W; Wiqas A; Vincent KD; Versteeg SG; Gupta AK
    Skinmed; 2019; 17(1):36-38. PubMed ID: 30888946
    [No Abstract]   [Full Text] [Related]  

  • 29. New Therapies for Psoriasis.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S71-3. PubMed ID: 27525355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infliximab associated new-onset psoriasis.
    Adams DR; Buckel T; Sceppa JA
    J Drugs Dermatol; 2006 Feb; 5(2):178-9. PubMed ID: 16485887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Our experience with infliximab in reclacitrant cases of psoriasis].
    Pereiro M; González-Vilas D; Sánchez-Aguilar D; Toribio J
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():43-7. PubMed ID: 19080991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis.
    Barland C; Kerdel FA
    Arch Dermatol; 2003 Jul; 139(7):949-50. PubMed ID: 12873907
    [No Abstract]   [Full Text] [Related]  

  • 33. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis.
    Wahie S; Alexandroff A; Reynolds NJ
    Clin Exp Dermatol; 2006 May; 31(3):460-1. PubMed ID: 16681606
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of pustular psoriasis with infliximab.
    Weishaupt C; Metze D; Luger TA; Ständer S
    J Dtsch Dermatol Ges; 2007 May; 5(5):397-9. PubMed ID: 17451384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Infliximab-induced remission of extensive plaque psoriasis.
    Amital H; Ingber A; Rubinow A
    Isr Med Assoc J; 2003 Nov; 5(11):827-8. PubMed ID: 14650114
    [No Abstract]   [Full Text] [Related]  

  • 36. Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect?
    Loi C; Patrizi A; Sechi A; Tartari F; Magnano M; Bardazzi F
    G Ital Dermatol Venereol; 2018 Aug; 153(4):590-591. PubMed ID: 29767491
    [No Abstract]   [Full Text] [Related]  

  • 37. Development of linear IgA bullous dermatosis in a patient with psoriasis taking ustekinumab.
    Becker JG; Mundi JP; Newlove T; Mones J; Shupack J
    J Am Acad Dermatol; 2012 Oct; 67(4):e150-1. PubMed ID: 22980274
    [No Abstract]   [Full Text] [Related]  

  • 38. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treating psoriasis patients with biologic agents.
    Pariser DM
    Manag Care; 2003 Dec; 12(12):50-7; discussion 57-9; quiz 60-2. PubMed ID: 14723104
    [No Abstract]   [Full Text] [Related]  

  • 40. [Legionella pneumonia in patients treated with infliximab].
    Vinter H; Nielsen HI
    Ugeskr Laeger; 2009 Jan; 171(4):247. PubMed ID: 19174042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.